Joint semi-supervised and contrastive learning enables domain generalization and multi-domain segmentation.

Journal: Medical image analysis
Published Date:

Abstract

Despite their effectiveness, current deep learning models face challenges with images coming from different domains with varying appearance and content. We introduce SegCLR, a versatile framework designed to segment images across different domains, employing supervised and contrastive learning simultaneously to effectively learn from both labeled and unlabeled data. We demonstrate the superior performance of SegCLR through a comprehensive evaluation involving three diverse clinical datasets of 3D retinal Optical Coherence Tomography (OCT) images, for the slice-wise segmentation of fluids with various network configurations and verification across 10 different network initializations. In an unsupervised domain adaptation context, SegCLR achieves results on par with a supervised upper-bound model trained on the intended target domain. Notably, we discover that the segmentation performance of SegCLR framework is marginally impacted by the abundance of unlabeled data from the target domain, thereby we also propose an effective domain generalization extension of SegCLR, known also as zero-shot domain adaptation, which eliminates the need for any target domain information. This shows that our proposed addition of contrastive loss in standard supervised training for segmentation leads to superior models, inherently more generalizable to both in- and out-of-domain test data. We additionally propose a pragmatic solution for SegCLR deployment in realistic scenarios with multiple domains containing labeled data. Accordingly, our framework pushes the boundaries of deep-learning based segmentation in multi-domain applications, regardless of data availability - labeled, unlabeled, or nonexistent.

Authors

  • Alvaro Gomariz
    F Hoffmann-La Roche AG, Basel, Switzerland. Electronic address: alvaro.gomariz@roche.com.
  • Yusuke Kikuchi
    Genentech Inc, CA, United States.
  • Yun Yvonna Li
    F Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Thomas Albrecht
    Institute of Pathology, Heidelberg University, Heidelberg, Germany.
  • Andreas Maunz
    Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
  • Daniela Ferrara
    Genentech, Inc., South San Francisco, California.
  • Huanxiang Lu
    Blue Brain Project, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015, Lausanne, Switzerland.
  • Orcun Goksel